The era of oral GLP-1 receptor agonists is acceleratingbut when comparing available Phase 2 clinical trial data, one molecule clearly established the highest efficacy before successfully completing Phase 3
Ann Pediatr Endocrinol Metab 2022;27(4):289-299
Metabolic indicators that may correlate with reduced GLP-1 activity include: Persistent hyperglycemia despite dietary modifications, particularly elevated postprandial (after-meal) blood glucose levels Difficulty achieving satiety after meals, leading to continued hunger and frequent snacking Progressive weight gain that is resistant to conventional dietary interventions Diagnosis of prediabetes or type 2 diabetes , conditions associated with impaired incretin response Metabolic syndrome features , including central obesity, hypertension, and dyslipidemia It is important to emphasize that these signs are not diagnostic of GLP-1 imbalance specifically, as they can result from numerous metabolic, endocrine, or lifestyle factors
limit of detection, 0.8 g/mL
Benefits: Provides antioxidants, protein, omega-3 fats, and fiber to support gut and metabolic health
Importantly, this wasnt just about numbers on a scale
